18 articles with ArcherDX
ArcherDX, Inc. today announced that Jason Myers, Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at Cowen's 2020 Liquid Biopsy Summit at 2:00 p.m. Eastern Daylight Time (EDT) / 12:00 p.m. Mountain Daylight Time (MDT).
ArcherDX, Inc. today announced that Jason Myers , Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at the Morgan Stanley 18 th Annual Global Healthcare Conference at 3:45 p.m. Eastern Daylight Time (EDT) / 1:45 p.m. Mountain Daylight Time (MDT).
ArcherDX, Inc. today announced that Jason Myers , Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Virtual Summit.
ArcherDX, Inc., UCL and the Francis Crick Institute announced an extension to utilize personalized, liquid biopsy-based research assays for the duration of the TRACERx program, a major lung cancer research initiative funded by Cancer Research UK.
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring
ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research
Aims to Inform use of Minimal Residual Disease (MRD) Monitoring in Clinical Trial Protocols and Future Therapy Optimization
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
AstraZeneca to Leverage ArcherDX's PCM Liquid Biopsy Technology to Facilitate Multiple Clinical Trials for Early-Stage Non-Small Cell Lung Cancer Therapies
ArcherDX, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its next-generation sequencing device under development as a companion diagnostic to detect neurotrophic receptor tyrosine kinase gene fusions that lead to the formation and growth of cancer.
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib)
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI ® (larotrectinib) Collaboration will focus on development of a companion diagnostic (CDx) for Vitrakvi ® , the first-in-class tyrosine kinase (TRK) inhibitor approved in the U.S. and Europe for adult and pediatric patients with TRK fusion cancer across all solid tumors. Vitrakvi has the largest and longest-term data set
ArcherDX, Inc. today announced the appointment of Jason Ryan , Chief Operating and Financial Officer at Magenta Therapeutics and former Chief Financial Officer at Foundation Medicine, to the company's Board of Directors and as the Chair of the Audit Committee.
STRATAFIDE™ Proprietary Test Designed to Enable Community Hospitals to Rapidly Deliver Accurate and Actionable Genomic Information to Cancer Patients and Providers in their Local Care Settings A Majority of Cancer Patients in Community Settings Fail to Receive Molecular Testing and Targeted Therapies(i)
ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan
ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Medical Devices Agency (PMDA) to detect MET exon 14 ( MET ex14) skipping alterations in tissue (RNA) and liquid biopsy (ctDNA) from patients with advan
ArcherDX, Inc., today announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Personalized Cancer Monitoring (PCM) technology, a bespoke, minimally-invasive and highly-sensitive product intended for early-stage cancer treatment monitoring and recurrence surveillance.
ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests
Co-marketing partnership to drive awareness of ArcherDX IVD products and increase access to vital genomic information in the community oncology care setting
ArcherDX, Inc., a molecular diagnostics company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced that Jason Myers, Ph.D., Chief Executive Officer, will present an overview of the company and its products at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
ArcherDX, Inc., a molecular diagnostics company developing breakthrough solutions to advance and enable the practice of personalized genomic medicine, today announced Mark Massaro has been appointed Chief Financial Officer.
ArcherDX, Inc., today announced the close of a $55 million Series C financing round led by Perceptive Advisors, which was joined by new investors Redmile Group, Soleus Capital, Driehaus Capital Management and ArrowMark Partners, as well as existing investors Sands Capital, Longwood Fund, PBM Capital and its affiliates, Boulder Ventures and others.
ArcherDX, Inc., a growth-stage molecular diagnostics company dedicated to developing breakthrough solutions that advance personalized genomic medicine, today announced a non-exclusive partnership with Illumina, Inc.